BrainsWay Ltd. Logo

BrainsWay Ltd.

BWAY.TA

(0.8)
Stock Price

1.581,00 ILA

-13.7% ROA

-19.17% ROE

-13.47x PER

Market Cap.

110.522.759,15 ILA

11.28% DER

0% Yield

-28.45% NPM

BrainsWay Ltd. Stock Analysis

BrainsWay Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BrainsWay Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (10%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.78x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 ROE

Negative ROE (-29.12%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-21.94%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-4), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

BrainsWay Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BrainsWay Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

BrainsWay Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BrainsWay Ltd. Revenue
Year Revenue Growth
2013 1.189.000
2014 3.380.000 64.82%
2015 6.800.000 50.29%
2016 11.524.000 40.99%
2017 11.145.000 -3.4%
2018 16.397.000 32.03%
2019 23.101.000 29.02%
2020 22.057.000 -4.73%
2021 29.657.000 25.63%
2022 27.177.000 -9.13%
2023 33.208.000 18.16%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BrainsWay Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2013 3.688.000
2014 6.438.000 42.72%
2015 4.103.000 -56.91%
2016 3.792.000 -8.2%
2017 5.343.000 29.03%
2018 6.156.000 13.21%
2019 7.876.000 21.84%
2020 5.823.000 -35.26%
2021 6.393.000 8.92%
2022 7.678.000 16.74%
2023 6.176.000 -24.32%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BrainsWay Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 1.429.000
2014 2.340.000 38.93%
2015 3.607.000 35.13%
2016 5.742.000 37.18%
2017 7.467.000 23.1%
2018 8.233.000 9.3%
2019 4.387.000 -87.67%
2020 4.722.000 7.09%
2021 5.784.000 18.36%
2022 6.854.000 15.61%
2023 4.632.000 -47.97%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BrainsWay Ltd. EBITDA
Year EBITDA Growth
2013 -951.000
2014 -6.869.000 86.16%
2015 -3.913.000 -75.54%
2016 -1.469.000 -166.37%
2017 -5.564.000 73.6%
2018 -4.402.000 -26.4%
2019 -6.583.000 33.13%
2020 -4.829.000 -36.32%
2021 -3.313.000 -45.76%
2022 -11.148.000 70.28%
2023 796.000 1500.5%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BrainsWay Ltd. Gross Profit
Year Gross Profit Growth
2013 990.000
2014 2.724.000 63.66%
2015 5.334.000 48.93%
2016 9.097.000 41.37%
2017 8.550.000 -6.4%
2018 12.808.000 33.24%
2019 17.972.000 28.73%
2020 16.999.000 -5.72%
2021 23.058.000 26.28%
2022 20.048.000 -15.01%
2023 24.684.000 18.78%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BrainsWay Ltd. Net Profit
Year Net Profit Growth
2013 -7.122.000
2014 -6.545.000 -8.82%
2015 -4.087.000 -60.14%
2016 -2.397.000 -70.5%
2017 -7.054.000 66.02%
2018 -6.479.000 -8.87%
2019 -10.328.000 37.27%
2020 -5.385.000 -91.79%
2021 -6.462.000 16.67%
2022 -13.349.000 51.59%
2023 -920.000 -1350.98%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BrainsWay Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 -1
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -1 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BrainsWay Ltd. Free Cashflow
Year Free Cashflow Growth
2013 -6.407.000
2014 -5.289.000 -21.14%
2015 -6.822.000 22.47%
2016 -2.810.000 -142.78%
2017 -4.452.000 36.88%
2018 -5.745.000 22.51%
2019 -10.555.000 45.57%
2020 -3.906.000 -170.23%
2021 -1.354.000 -188.48%
2022 -9.759.000 86.13%
2023 842.000 1259.03%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BrainsWay Ltd. Operating Cashflow
Year Operating Cashflow Growth
2013 -2.363.000
2014 -3.793.000 37.7%
2015 -4.552.000 16.67%
2016 -2.402.000 -89.51%
2017 -3.467.000 30.72%
2018 -3.773.000 8.11%
2019 -7.244.000 47.92%
2020 -1.436.000 -404.46%
2021 884.000 262.44%
2022 -9.759.000 109.06%
2023 1.356.000 819.69%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BrainsWay Ltd. Capital Expenditure
Year Capital Expenditure Growth
2013 4.044.000
2014 1.496.000 -170.32%
2015 2.270.000 34.1%
2016 408.000 -456.37%
2017 985.000 58.58%
2018 1.972.000 50.05%
2019 3.311.000 40.44%
2020 2.470.000 -34.05%
2021 2.238.000 -10.37%
2022 0 0%
2023 514.000 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BrainsWay Ltd. Equity
Year Equity Growth
2014 15.577.000
2015 12.895.000 -20.8%
2016 10.287.000 -25.35%
2017 12.721.000 19.13%
2018 6.952.000 -82.98%
2019 24.220.000 71.3%
2020 19.634.000 -23.36%
2021 57.324.000 65.75%
2022 45.397.000 -26.27%
2023 41.218.000 -10.14%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BrainsWay Ltd. Assets
Year Assets Growth
2014 25.771.000
2015 22.243.000 -15.86%
2016 19.964.000 -11.42%
2017 27.030.000 26.14%
2018 23.602.000 -14.52%
2019 38.736.000 39.07%
2020 34.011.000 -13.89%
2021 75.732.000 55.09%
2022 64.477.000 -17.46%
2023 59.774.000 -7.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BrainsWay Ltd. Liabilities
Year Liabilities Growth
2014 10.194.000
2015 9.348.000 -9.05%
2016 9.677.000 3.4%
2017 14.309.000 32.37%
2018 16.650.000 14.06%
2019 14.516.000 -14.7%
2020 14.377.000 -0.97%
2021 18.408.000 21.9%
2022 19.080.000 3.52%
2023 18.556.000 -2.82%

BrainsWay Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.87
Net Income per Share
-0.25
Price to Earning Ratio
-13.47x
Price To Sales Ratio
3.84x
POCF Ratio
-32.16
PFCF Ratio
-20.31
Price to Book Ratio
2.68
EV to Sales
2.31
EV Over EBITDA
-8.2
EV to Operating CashFlow
-19.41
EV to FreeCashFlow
-12.24
Earnings Yield
-0.07
FreeCashFlow Yield
-0.05
Market Cap
0,11 Bil.
Enterprise Value
0,07 Bil.
Graham Number
2.63
Graham NetNet
0.9

Income Statement Metrics

Net Income per Share
-0.25
Income Quality
0.42
ROE
-0.19
Return On Assets
-0.14
Return On Capital Employed
-0.18
Net Income per EBT
1.05
EBT Per Ebit
0.83
Ebit per Revenue
-0.33
Effective Tax Rate
-0.05

Margins

Sales, General, & Administrative to Revenue
0.2
Research & Developement to Revenue
0.26
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.73
Operating Profit Margin
-0.33
Pretax Profit Margin
-0.27
Net Profit Margin
-0.28

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.1
Free CashFlow per Share
-0.16
Capex to Operating CashFlow
0.59
Capex to Revenue
-0.07
Capex to Depreciation
-1.5
Return on Invested Capital
-0.22
Return on Tangible Assets
-0.14
Days Sales Outstanding
43.33
Days Payables Outstanding
23.23
Days of Inventory on Hand
165.09
Receivables Turnover
8.42
Payables Turnover
15.71
Inventory Turnover
2.21
Capex per Share
-0.06

Balance Sheet

Cash per Share
1,33
Book Value per Share
1,24
Tangible Book Value per Share
1.24
Shareholders Equity per Share
1.24
Interest Debt per Share
0.08
Debt to Equity
0.11
Debt to Assets
0.08
Net Debt to EBITDA
5.4
Current Ratio
6.36
Tangible Asset Value
0,04 Bil.
Net Current Asset Value
0,03 Bil.
Invested Capital
0.11
Working Capital
0,04 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
3402500
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BrainsWay Ltd. Dividends
Year Dividends Growth

BrainsWay Ltd. Profile

About BrainsWay Ltd.

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

CEO
Mr. Hadar Levy
Employee
134
Address
Bynet Building
Jerusalem, 9777518

BrainsWay Ltd. Executives & BODs

BrainsWay Ltd. Executives & BODs
# Name Age
1 Mr. Hadar Levy
Chief Executive Officer
70
2 Mr. Menachem C. Klein Esq.
Vice President, General Counsel & Corporate Secretary
70
3 Dr. Aron Tendler
Chief Medical Officer
70
4 Mr. Ido Marom
Chief Financial Officer
70
5 Mr. Avner Hagai
Founder & Director
70
6 Prof. Abraham Zangen
Co-Founder, Member of Scientific Advisory Board & Director
70
7 Mr. Christopher J. Boyer Ph.D.
Vice President of Global Marketing
70
8 Dr. Yiftach Roth Ph.D.
Founder & Chief Scientific Officer
70

BrainsWay Ltd. Competitors

BrainsWay Ltd. Logo
BrainsWay Ltd.

BWAY

(1.0)
Kamada Ltd. Logo
Kamada Ltd.

KMDA.TA

(1.2)
IceCure Medical Ltd Logo
IceCure Medical Ltd

ICCM.TA

(0.8)
Compugen Ltd. Logo
Compugen Ltd.

CGEN.TA

(1.0)